This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Merck & Company (MRK) Receives a Buy from BMO Capital

Tipranks - Tipranks - Thu Aug 6, 6:46AM CDT

In a report released today, Evan Seigerman from BMO Capital reiterated a Buy rating on Merck & Company, with a price target of $142.00.

Claim 55% Off TipRanks

Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Pfizer. According to TipRanks, Seigerman has an average return of 7.7% and a 56.07% success rate on recommended stocks.

In addition to BMO Capital, Merck & Company also received a Buy from Guggenheim’s Vamil Divan in a report issued today. However, on July 22, Bernstein maintained a Hold rating on Merck & Company (NYSE: MRK).

See the top stocks recommended by analysts >>

Based on Merck & Company’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $16.29 billion and a GAAP net loss of $4.24 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $5.08 billion

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).